|
May 19
|
CEL-SCI Announces Combination of Common Stock
|
|
May 15
|
CEL-SCI Reports Fiscal Second Quarter 2025 Financial Results
|
|
May 14
|
Cel-Sci: Fiscal Q2 Earnings Snapshot
|
|
Mar 18
|
CEL-SCI Announces Closing of $2.5 Million Offering
|
|
Mar 17
|
CEL-SCI Announces Pricing of $2.5 Million Offering
|
|
Mar 17
|
CEL-SCI’s Head and Neck Cancer Registration Study Protocol Clears FDA Review—in Talks with Potential Partners Interested in Commercialization of Multikine
|
|
Mar 14
|
Journal of the American Medical Association (JAMA) Study Provides Further Evidence that CEL-SCI’s Multikine Can Treat Unmet Need in ~70% of Head and Neck Patients Based on PD-L1 Expression
|
|
Feb 14
|
Cel-Sci: Fiscal Q1 Earnings Snapshot
|
|
Feb 10
|
CVM: Fiscal Year 2024 Results
|
|
Dec 31
|
CEL-SCI Announces Closing of $5 Million Offering
|
|
Dec 30
|
CEL-SCI Announces Pricing of $5 Million Public Offering
|